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Abstract  
Sialic acids cap the glycans of cell surface glycoproteins and glycolipids. They are involved in a 
multitude of biological processes and aberrant sialic acid expression is associated with several 
pathologies. Sialic acids modulate the characteristics and functions of glycoproteins and regulate cell-
cell as well as cell-extracellular matrix interactions. Pathogens such as influenza virus use sialic acids 
to infect host cells and cancer cells exploit sialic acids to escape from the host’s immune system. The 
introduction of unnatural sialic acids with different functionalities into surface glycans enables the 
study of the broad biological functions of these sugars and presents a therapeutic option to intervene 
with pathological processes involving sialic acids. Multiple chemically modified sialic acid analogues 
can be directly utilized by cells for sialoglycan synthesis. Alternatively, analogues of the natural sialic 
acid precursor sugar N-Acetylmannosamine (ManNAc) can be introduced into the sialic acid 
biosynthesis pathway resulting in the intracellular conversion into the corresponding sialic acid 
analogue. Both, ManNAc and sialic acid analogues, have been employed successfully for a large 
variety of glycoengineering applications such as glycan imaging, targeting toxins to tumor cells, 
inhibiting pathogen binding, or altering immune cell activity. However, there are significant 
differences between ManNAc and sialic acid analogues with respect to their chemical modification 
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Introduction 
Glycans of most vertebrate cells and several microorganisms are frequently terminated by sialic acids, 
a family of negatively charged sugars derived from 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid 
(KDN) that share a nine-carbon backbone. The most abundant sialic acid family member in humans 
and other mammals is N-Acetylneuraminic acid (Neu5Ac) that carries an N-acetyl group present on C-
5 of the sialic acid backbone (Figure 1) (Inoue, S. and Kitajima, K. 2006, Varki, A., Schnaar, R.L., et 
al. 2015b). Other natural modifications of the sialic acid backbone give rise to family members such as 
N-Glycolylneuraminic acid (Neu5Gc), 9-O-acetyl (Neu5Ac9Ac) or 9-lactosyl (Neu5Ac9Lt) sialic acid 
and also O-sulfation and O-methylation of sialic acids occur (Chen, X. and Varki, A. 2010, Schauer, 
R. 2009, Varki, A., Schnaar, R.L., et al. 2015b). Strikingly, the biological functions of many of these 
sialic acid family members are poorly understood. The different sialic acid types are linked via three 
linkage types (α2,3, α2,6, or α2,8) by twenty sialyltransferase isoenzymes to glycans. This 
combinatorial diversity enables cells to produce a highly diverse repertoire of sialoglycans referred to 
as the sialome (Cohen, M. and Varki, A. 2010, Varki, A., Schnaar, R.L., et al. 2015b).  
Located at the outer end of glycans, sialic acids are at the center of numerous molecular interactions at 
the cell surface. For example, sialic acids influence the biochemical properties and functions of 
glycoproteins and lipids, mask underlying glycans, mediate cell adhesion and migration and serve as 
ligands for sialic acid-binding proteins like factor H, selectins and the Siglecs (Schauer, R. 2009, 
Varki, A., Schnaar, R.L., et al. 2015b). Factor H can bind sialic acids on the surface of host cells to 
avoid complement activation and the selectin family interacts with sialic acids during lymphocyte 
trafficking and extravasation to sites of inflammation (Varki, A. 2007, Varki, A. and Gagneux, P. 
2012). Sialic acids are also important immune regulators by interacting with sialic acid-binding 
immunoglobulin-like lectins (Siglecs), a family of immunomodulatory receptors widely expressed 
throughout the immune system (Büll, C., Heise, T., et al. 2016, Macauley, M.S., Crocker, P.R., et al. 
2014, Varki, A., Schnaar, R.L., et al. 2015a). Next to their vital role in physiological processes, a 
number of pathologies are associated with sialic acids and their biosynthesis. Many human pathogens 
use sialic acids on host cells as attachment site or decorate their surface with host sialic acids as 
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Langereis, J.D., et al. 2018, Stencel-Baerenwald, J.E., Reiss, K., et al. 2014, Wasik, B.R., Barnard, 
K.N., et al. 2016). Aberrant expression of sialoglycans supports tumor growth, metastasis and limits 
anti-tumor immune responses (Boligan, K.F., Mesa, C., et al. 2015, Büll, C., Boltje, T.J., et al. 2018, 
Büll, C., den Brok, M.H., et al. 2014, Büll, C., Stoel, M.A., et al. 2014, Pinho, S.S. and Reis, C.A. 
2015, Schultz, M.J., Swindall, A.F., et al. 2012). Furthermore, genetic defects in sialic acid 
biosynthesis have been identified and may result in clinical phenotypes such as myopathy, sialuria or 
abnormal neuronal development (Aula, N., Salomaki, P., et al. 2000, van Karnebeek, C.D., Bonafe, L., 
et al. 2016, Varki, A. 2008, Willems, A.P., van Engelen, B.G., et al. 2016).  
The importance of the expression and recognition of sialic acids in human biology and pathology 
makes them potential therapeutic targets. Therefore, approaches to track and alter sialic acid 
expression or to change their biochemical properties of sialic acids are not only essential to study their 
biological functions, but are also key to their application in biotechnological processes or as therapy in 
the future. Sialic acid glycoengineering, the introduction of unnatural sialic acids with different 
chemical properties into sialoglycans, is such an approach that is increasingly applied in the field of 
glycoscience and beyond. Chemically modified analogues of N-acetylmannosamine, the biological 
precursor of sialic acid, or sialic acid analogues can be introduced into the metabolic sialic acid 
biosynthesis pathway resulting in their incorporation into sialoglycans (Figure 2). This approach also 
allows to image sialoglycans in living organisms or to alter their binding to sialic acid-binding lectins. 
Although ManNAc analogues and sialic acid analogues both are useful tools for sialic acid 
glycoengineering, there are significant differences in the chemical modification potential and cellular 
metabolism of both sugars that have important implications for their use in glycoengineering 
experiments.  
Here we review the differences between ManNAc and sialic acid analogues and the consequences 
hereof on labeling efficiency, selectivity for the sialic acid biosynthesis pathway and effects on 
biological processes in the cell. Finally, we discuss the implications of these differences for the use of 
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Sialic acid glycoengineering using ManNAc and sialic acid analogues 
Two approaches are used in sialic acid glycoengineering, either selective exo-enzymatic labeling of 
sialic acids or metabolic labeling via the incorporation of unnatural ManNAc or sialic acids. In this 
review, we focus on the more commonly used metabolic incorporation approach and the reader is 
referred to other timely publications covering selective exo-enzymatic labeling (Briard, J.G., Jiang, H., 
et al. 2018, Mbua, N.E., Li, X.R., et al. 2013, Nischan, N. and Kohler, J.J. 2016, Sun, T.T., Yu, S.H., 
et al. 2016). Metabolic labeling of sialic acids can be achieved by the incorporation of unnatural 
biosynthetic precursors into the cell’s sialoglycans (see Figure 2 for a detailed description of the sialic 
acid biosynthesis). Two precursors to infiltrate the sialic acid biosynthesis are typically utilized, 
ManNAc and Neu5Ac. ManNAc is converted into Neu5Ac by three enzymes, UDP-GlcNAc 2-
epimerase/ManNAc kinase (GNE) that produces ManNAc-6-phosphate, N-acetylneuraminate synthase 
(NANS) which produces Neu5Ac-9-phosphate, and finally Neu5Ac-9-P-phosphatase (NANP) which 
produces Neu5Ac. In addition to the de novo biosynthesis, vertebrate cells can salvage exogenous 
sialic acids from dietary sources, such as the non-human Neu5Gc, and certain pathogenic 
microorganisms can utilize sialic acids derived from host cells (Freeze, H.H., Hart, G.W., et al. 2015, 
Heise, T., Langereis, J.D., et al. 2018, Severi, E., Hood, D.W., et al. 2007, Varki, A., Schnaar, R.L., et 
al. 2015b). Neu5Ac is activated with cytidine monophosphate (CMP) in the nucleus by the CMP sialic 
acid synthase (CMAS) to produce CMP-sialic acid which is transported to the Golgi system and 
incorporated into sialoglycans by the sialyltransferases (Kajihara, Y., Nishigaki, S., et al. 2011). 
Cellular uptake of unnatural ManNAc and sialic acid analogues by endogenous transport mechanisms 
is poor due to their polar nature and the lack of efficient uptake mechanisms in mammalian cells. 
Studies using radioactive-labeled sugars and other reporter groups showed that concentrations in the 
range of 1-20 mM need to be added to cell cultures in vitro to achieve robust incorporation into 
glycans (Bardor, M., Nguyen, D.H., et al. 2005, Diaz, S. and Varki, A. 1985). Analogues are therefore 
often acetylated to facilitate passive diffusion through the plasma membrane and allow working 
concentrations of 1-200 µM (Wang, Z., Du, J., et al. 2009). The acetyl esters are removed 
intracellularly by esterases as only the unprotected sugar can be used by the sialylation machinery 
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ManNAc and sialic acid can further be modified to obtain sugar analogues with different 
functionalities. Depending on the modification, analogues can be produced that inhibit enzymes 
involved in sialylation and therefore act as metabolic inhibitor of sialic acid expression. For instance, 
sialic acid with an axial fluorine on C-3 is a potent sialyltransferase inhibitor that was applied to 
enhance anti-tumor immunity or to reduce metastasis in mouse models (Büll, C., Boltje, T.J., et al. 
2018, Büll, C., Boltje, T.J., et al. 2015, Büll, C., Boltje, T.J., et al. 2013, Macauley, M.S., Arlian, 
B.M., et al. 2014, Rillahan, C.D., Antonopoulos, A., et al. 2012). On the contrary, modifications to 
ManNAc or sialic acid that are tolerated by the sialylation enzymes enable the metabolic introduction 
of sialic acid analogues into glycans. Currently, ManNAc and sialic acid analogues with different 
functionalities have been developed for sialic acid glycoengineering (Figure 3) (Cheng, B., Xie, R., et 
al. 2016, Sminia, T.J., Zuilhof, H., et al. 2016, Wratil, P.R., Horstkorte, R., et al. 2016).  
Initially, ManNAc derivatives with increasingly aliphatic C-2 acyl chains were used to probe the 
promiscuity of the sialic acid biosynthesis pathway (Wratil, P.R., Horstkorte, R., et al. 2016). Several 
ManNAc analogues are tolerated by the sialylation machinery and hence are converted into the 
corresponding sialic acid analogues inside the cell leading to their presentation on cell surface glycans. 
For instance, Reutter and colleagues generated acyl-chain modified ManNAc analogues that can be 
transformed into the corresponding sialic acid analogues which either enhanced or abrogated 
recognition by polyoma viruses (Keppler, O.T., Stehling, P., et al. 1995). Bertozzi and co-workers 
showed that small chemical reporter groups could also be added to the C-2 acyl chain of ManNAc 
derivatives resulting in sialic acid analogue carrying the modification on C-5 (Sletten, E.M. and 
Bertozzi, C.R. 2009). A prime example is the azidoacetyl functionality which can undergo a so-called 
bioorthogonal reaction to introduce a fluorescent label onto sialic acids (Saxon, E. and Bertozzi, C.R. 
2000). Using this approach sialic acid localization and turnover can be imaged in cell lines, zebrafish 
embryos or tumors in mouse models (Belardi, B., de la Zerda, A., et al. 2013, Dehnert, K.W., Baskin, 
J.M., et al. 2012, Neves, A.A., Stockmann, H., et al. 2011, Prescher, J.A., Dube, D.H., et al. 2004, 
Rong, J., Han, J., et al. 2014, Xie, R., Dong, L., et al. 2016). Moreover, introducing ManNAc or sialic 
acid analogues into the glycans of living cells enables purification of sialylated proteins, targeted 









niversity user on 27 M
arch 2019
Siglecs or pathogenic lectins (Büll, C., Heise, T., et al. 2016, Büll, C., Heise, T., et al. 2017, Heise, T., 
Büll, C., et al. 2017, Spiciarich, D.R., Nolley, R., et al. 2017, Wang, H., Wang, R., et al. 2017). The 
versatile applications of sialic acid glycoengineering with ManNAc or sialic acid analogues have been 
reviewed by others (Badr, H.A., AlSadek, D.M.M., et al. 2017, Cheng, B., Xie, R., et al. 2016, Du, J., 
Meledeo, M.A., et al. 2009, Rouhanifard, S.H., Nordstrom, L.U., et al. 2013, Sminia, T.J., Zuilhof, H., 
et al. 2016, Wratil, P.R., Horstkorte, R., et al. 2016). Although ManNAc and sialic acid analogues are 
both used for a wide range of applications, little attention has been paid to key differences in their 
chemical modification potential and metabolic fate that co-determine their incorporation efficiency 
into sialoglycans, selectivity for the sialic acid pathway and effects on biological processes (Table I). 
These differences have important implications for the use of ManNAc and sialic acid analogues and 
should be taken into consideration for sialic acid glycoengineering.  
 
Modification potential and synthesis of ManNAc and sialic acid analogues 
The differences in structure and cellular metabolism between ManNAc and sialic acid define the 
spectrum of analogues that can be developed for sialic acid glycoengineering (Figure 3). 
Modifications to the ManNAc backbone need to be tolerated by GNE, NANS and NANP in order to 
yield the respective sialic acid analogue. The C-2 position of ManNAc can be modified in one step by 
performing an acylation reaction and C-2 substituted ManNAc will result in the formation of the 
corresponding C-5 modified sialic acid (Wratil, P.R., Horstkorte, R., et al. 2016). This makes 
ManNAc an attractive choice if modifications on this position need to be incorporated. In addition, the 
C-4 position of ManNAc can be modified leading to C-7 modified sialic acid presentation in the cell. 
The chemical synthesis of C-4 modified ManNAc derivatives can be achieved in five steps and 
various substituents have been introduced already at C-4 (Thomson, R. and von Itzstein, M. 1995). 
From a synthesis perspective, ManNAc analogues are readily available and therefore many sialic acid 
glycoengineering reagents used so far are based on ManNAc precursors. However, there are three 
major limitations for the development of ManNAc analogues for sialic acid engineering (Table I). 
First, modifications at certain positions on ManNAc are not tolerated by the three enzymes converting 
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reactive site in the conversion to sialic acid by NANS. Furthermore, the C-6 position of ManNAc is 
phosphorylated by GNE and hence modifications at this site would interfere with the production of 
ManNAc-6-phosphate, the substrate for NANS (Blume, A., Benie, A.J., et al. 2004, Lawrence, S.M., 
Huddleston, K.A., et al. 2000, Oetke, C., Brossmer, R., et al. 2002, Tanner, M.E. 2005). Potentially, 
unphosphorylated ManNAc may be converted into sialic acid by sialic acid aldolase or GlcNAc 6-
kinase but both are likely very inefficient processes (Hinderlich, S., Berger, M., et al. 2000, Sparks, 
M.A., Williams, K.W., et al. 1993). Although not directly utilized in sialic acid synthesis, the C-3 
hydroxyl of ManNAc can also not be modified since it will be converted into the endocyclic oxygen in 
sialic acid. Second, the size of the modifications that can be carried through the sialic acid biosynthesis 
pathway is especially restricted by GNE which carries out the phosphorylation of ManNAc on the C-6 
position to yield ManNAc-6-phosphate. Acyl modifications larger than five carbon atoms or branched 
structures on the C-2 position of ManNAc impede the enzymatic conversion by GNE (Jacobs, C.L., 
Goon, S., et al. 2001, Viswanathan, K., Lawrence, S., et al. 2003). Third, not all potential sialic acid 
analogues can be generated utilizing ManNAc precursors since it undergoes an aldol reaction with 
phosphoenolpyruvate catalyzed by NANS to form sialic acid. Hence, the C-3 and C-4 position of 
sialic acid cannot be modified starting from ManNAc since it is derived from phosphoenolpyruvate or 
is a reactive center in the aldol condensation, respectively. These three factors largely limit the 
development of ManNAc analogues for incorporation into cell surface sialic acids, but can be explored 
alternatively for the development of inhibitors of ManNAc conversion to sialic acids (Nieto-Garcia, 
O., Wratil, P.R., et al. 2016, Wratil, P.R., Rigol, S., et al. 2014). 
Sialic acid is a more versatile reagent as it bypasses the metabolic conversion by GNE, NANS and 
NANP and therefore has a broader modification potential than ManNAc analogues (Table I). Except 
from C-1 and C-2 that are required for CMP activation and glycosidic linkage formation, sialic acid 
can potentially be modified at positions C-3 to C-9 since these positions are not directly involved in 
further metabolism (Büll, C., Heise, T., et al. 2016). Indeed, numerous modifications at the C-5 and C-
9 of sialic acid are well tolerated and efficiently incorporated (Cheng, B., Xie, R., et al. 2016). 
Compared to ManNAc, the chemical modification of sialic acid is more challenging as this sugar 
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therefore requires more elaborate protecting group strategies (Hemeon, I. and Bennet, A.J. 2007, Yu, 
C.C. and Withers, S.G. 2015). However, the more complicated scaffold of sialic acid provides more 
freedom to introduce unnatural modifications on the positions C-3 to C-9 with exception of the oxygen 
bound C-6. Access to C-3 modified sialic acids can be achieved by the use of 2-deoxy-2,3-dehydro-N-
acetyl-neuraminic acid (DANA) derivatives in which the double bond can undergo electrophilic 
addition reactions. The C-4 positions can be modified using a nucleophilic addition to a sialic acid 4,5-
oxazoline precursor or by using protecting group strategies and utilizing the intrinsic reactivity of the 
4-OH. Functionalizing the C-5 position chemically requires cleavage of the acetamide, which requires 
harsh conditions and protection of the anomeric center to avoid side products (Büll, C., Heise, T., et al. 
2015). The C-7 and C-8 hydroxyl groups are of low reactivity and strategies to modify them 
selectively require multiple protecting group manipulations. The C-9 hydroxyl group is the only 
primary alcohol in sialic acid and can be modified with good selectivity in the presence of other 
reactive groups. C-9 azido sialic acid is therefore readily available and a popular labeling reagent 
(Gross, H.J., Bunsch, A., et al. 1987, Han, S., Collins, B.E., et al. 2005, Xie, R., Dong, L., et al. 2016).  
In addition to the chemical synthesis of sialic derivatives, a chemo-enzymatic strategy can also be 
employed. N-acetylneuraminic acid lyase (NAL) is a bacterial aldolase capable of breaking down 
sialic acid into ManNAc and pyruvate. By using an excess of ManNAc or pyruvate, however, NAL 
can also catalyze the reverse reaction and hence modified ManNAc and pyruvate derivatives can be 
utilized to obtain the corresponding sialic acid analogue. For example, the use of fluoro pyruvate leads 
to the formation of 3-fluoro sialic acid that inhibits sialoglycan biosynthesis (Büll, C., Boltje, T.J., et 
al. 2013, Burkart, M.D., Vincent, S.P., et al. 1999, Heise, T., Langereis, J.D., et al. 2018, Rillahan, 
C.D., Antonopoulos, A., et al. 2012). Modifications on the ManNAc scaffold at C-2, C-4 and C-6 can 
be tolerated by NAL and hence yields C-5, C-7 and C-9 modified sialic acids (Cheng, B., Xie, R., et 
al. 2016). Out of the modifiable sites present in sialic acid only the C-3, C-5, C-7 and C-9 have been 
explored for sialic acid glycoengineering to date (Büll, C., Heise, T., et al. 2016) (Figure 3). Utilizing 
other positions (C-4 and C-8) with unnatural moieties for sialic acid glycoengineering is still 
unexplored. Elegant chemical procedures to make these derivatives available are therefore needed to 
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Differences in the cellular utilization of ManNAc and sialic acid analogues 
ManNAc and sialic acid, and hence their analogues, follow a different metabolic fate inside the cell, 
although their metabolism is not understood in all detail. Exogenous ManNAc and its unprotected 
analogues have been suggested to enter the cell via a so far unknown transporter system and are 
converted to sialic acids in the cytoplasm as depicted in Figure 2 (Bardor, M., Nguyen, D.H., et al. 
2005). Sialic acids and unprotected analogues enter the cell most likely via pinocytosis and 
independent from clathrin as suggested by Neu5Gc uptake experiments in the presence of the 
inhibitors amiloride and genistein, respectively (Bardor, M., Nguyen, D.H., et al. 2005). Further 
studies have shown that exogenous sialic acids can exit the lysosome via the sialic acid transporter 
sialin (SLC17A5) and are directly available for CMP activation and sialylation (Gilormini, P.A., Lion, 
C., et al. 2016, Vanbeselaere, J., Vicogne, D., et al. 2013) (Table 1). Foulquier and co-workers 
illustrated the different cellular fate of ManNAc and sialic acids using unprotected C-5 alkyne-
modified versions abbreviated ManNAl and SiaNAl, respectively. SiaNAl was clearly detectable 
inside the Golgi compartment already two hours after addition to the culture, but labeling derived from 
ManNAl was detected only after five to seven hours (Gilormini, P.A., Lion, C., et al. 2016). This 
difference in kinetics supports the idea that sialic acid analogues become readily available for 
sialoglycan synthesis, whereas ManNAc analogues have to be converted by GNE, NANS or NANP 
first. Another possibility is that the alkyne reporter group of ManNAl could interfere with the 
enzymatic conversion into sialic, which should be addressed in future studies. Overall, the different 
metabolism of ManNAc and sialic acid analogues has important consequences for their incorporation 
efficiency, selectivity and effects on biological processes. 
 
Incorporation Efficiency  
The incorporation of ManNAc and sialic acid analogues into cell surface sialoglycans can be analyzed 
with several methods. For example, radioactivity, mass spectrometry or HPLC are used to quantify the 
levels of modified cell surface sialic acids and azide- or alkyne-modified sialic acids can be quantified 
after biorthogonal reaction to fluorophores (Sminia, T.J., Zuilhof, H., et al. 2016, Wratil, P.R., 
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versus modified surface sialic acids or as relative fluorescent signal, respectively. Next to the 
differences in ManNAc and sialic acid metabolism, also other factors such as the type and position of 
the reporter, the expression of genes involved in sialic acid biosynthesis as well as levels of competing 
endogenous sugars influence incorporation (Badr, H.A., AlSadek, D.M.M., et al. 2017, Pham, N.D., 
Fermaintt, C.S., et al. 2015). In the case of the frequently used peracetylated analogues that need to be 
deacetylated by intracellular esterases, the labeling efficiency is also depending on expression levels of 
esterases and the effect of the modifications on esterase activity (Pham, N.D., Fermaintt, C.S., et al. 
2015, Wang, Z., Du, J., et al. 2009). Despite these variables, the incorporation efficiency of ManNAc 
and sialic acid analogues can be compared when using the same reporter and equimolar 
concentrations. 
In a direct comparison, Luchansky and colleagues showed that various, unprotected C-5 ketone 
modified ManNAc analogues were incorporated poorly or not at all while the corresponding sialic acid 
acids showed efficient labeling as detected by flow cytometry after conjugation with fluorescein. For 
instance N-levulinoyl modified sialic acid (SiaLev) was incorporated three times higher relative to 
ManLev (Luchansky, S.J., Goon, S., et al. 2004). Interestingly, azide-modified ManNAc and sialic 
acid showed similar incorporation efficiencies, but when a photocrosslinkable aryl group was used as 
reporter the ManNAc analogue was barely incorporated whereas high levels of aryl-containing sialic 
acids were found at the cell surface. Similar results were also obtained with peracetylated analogues 
that passively diffuse through the cell membrane. In a comparative study, Dafik and colleagues found 
that various peracetylated sialic acid analogues carrying fluorine modifications on the C-5 position 
were incorporated with higher efficiency compared to their mannosamine counterparts as measured by 
HPLC-based detection of fluorine groups in membrane preparations relative to untreated cells (Dafik, 
L., d’Alarcao, M., et al. 2008). Whereas fluorinated sialic acids analogues replaced up to 90 % of the 
natural sialic acids at the cell surface, the corresponding fluorinated mannosamines replaced maximum 
50 % at equimolar concentrations. In line with these findings, our group found that THP-1, Jurkat, 
HEK293 and HL-60 cells treated with peracetylated C-5 azido sialic acid (Ac5SiaNAz) and C-5 
propargyloxycarbonyl sialic acid (Ac5SiaNPoc) had 2-4 times higher fluorescence intensity compared 
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glycoprotein level, we found that human hepatocytes could incorporate Ac5SiaNPoc, but not 
Ac4ManNPoc into the sialic acids of transferrin, supporting the other studies that show higher 
incorporation efficiency of sialic acid analogue compared to ManNAc analogues.  
So far, only few studies have directly compared the incorporation efficiency of ManNAc and SiaNAc 
analogues in vivo. Our group has found that systemically administered Ac5SiaNPoc resulted in two 
times or more labeling of mouse organs compared to the ManNAc counterpart after reaction to 
fluorescent azide biotin (Büll, C., Heise, T., et al. 2015). Similarly, Cheng and co-workers showed that 
liposome encapsulated C-9-modified azido sialic acid resulted in potent labeling of sialoglycans in the 
mouse brain whereas azidomannosamine-containing liposomes resulted in no labeling (Xie, R., Dong, 
L., et al. 2016). Free, peracetylated C-9 azido sialic acid or Ac4ManNAz were not incorporated into 
brain sialoglycans, most likely because they are unable to pass the blood-brain barrier. These findings 
are further supported by experiments showing that incorporation of systemically administered 
peracetylated N-propanoylmannosamine (Ac4ManNProp) or Ac4ManNAz into brain sialoglycans is 
scarce whereas they are incorporated in most other organs (Gagiannis, D., Gossrau, R., et al. 2007, 
Shajahan, A., Parashar, S., et al. 2017). The reason why liposome-encapsulated azido sialic acids were 
incorporated into brain sialoglycans, but not liposome-encapsulated ManNAz remains to be 
investigated. Noteworthy, labeling of brain sialoglycans with azidomannosamine was recently 
achieved by intracranial injection or by coupling the ManNAc analogue to neuroactive carriers that 
pass the blood-brain barrier (Shajahan, A., Parashar, S., et al. 2017). The performance of 
corresponding sialic acid analogues has not been compared to the ManNAc analogues in this study, 
and would be interesting to address in further experiments. 
Collectively, most in vitro studies and few in vivo experiments advocate that sialic acid analogues are 
incorporated with higher efficiency compared to their ManNAc congener (Table II). This difference is 
potentially caused by the more extensive metabolism of ManNAc analogues, whereas sialic acid 
analogues can directly be used for sialylation. Modifications of ManNAc have to be tolerated by the 
ManNAc kinase domain of GNE (MNK) as well as NANS and NANP to produce the respective sialic 
acid analogue. Especially, tolerance of the MNK domain of GNE for the reporter appears to be rate-
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Goon, S., et al. 2001, Keppler, O.T., Hinderlich, S., et al. 1999). Interestingly, in cells with low or 
silenced GNE expression, sialic acid engineering with ManNAc analogues is highly efficient 
compared to control cells, presumably due to the low levels of competing endogenous ManNAc 
(Mantey, L.R., Keppler, O.T., et al. 2001, Moller, H., Bohrsch, V., et al. 2011, Oetke, C., Hinderlich, 
S., et al. 2003). The corresponding sialic acid analogues were not tested in this context. Future studies 
should investigate further details of ManNAc and sialic acid metabolism and more comparative 




The sialic acid biosynthesis pathway is unique as compared to other carbohydrates used for 
glycosylation. Sialic acids are produced from their dedicated precursor sugar ManNAc that is first 
converted to ManNAc-6-P and then condensed with phosphoenolpyruvate to form sialic acid. 
Furthermore, sialic acids are the only sugar that uses CMP as nucleotide sugar donor and this 
activation step takes place in the nucleus for unknown reasons (Angata, T. and Varki, A. 2002, Freeze, 
H.H., Hart, G.W., et al. 2015, Varki, A., Schnaar, R.L., et al. 2015b, Willems, A.P., van Engelen, 
B.G., et al. 2016). This unique biosynthesis pathway implies that ManNAc and sialic acid analogues 
are specifically used for sialoglycan synthesis. However, there is evidence that ManNAc analogues 
and possibly sialic acid analogues can also be converted into carbohydrates other than sialic acid 
(Table II). Early metabolic labeling experiments in cell lines with radioactive ManNAc by Varki and 
co-workers showed that next to the sialic acids, radioactive label was derived also from other 
membrane components (Diaz, S. and Varki, A. 2009, Varki, A. 1991). These findings suggest that 
intracellular ManNAc is not exclusively used for sialic acid biosynthesis, but can be converted into 
other carbohydrates as well. In line with this observation, others and our own group provided evidence 
that ManNAc analogues are metabolized into different glycan types. Splenocytes or tumors isolated 
from mice that were injected with Ac4ManNAz showed strong labeling of surface glycans. Upon 
treatment with sialidase, the labeling signal was reduced by only 15 %, indicating that the label was 
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Stockmann, H., et al. 2011). Similarly, we observed that Ac4ManNPoc was still incorporated into 
glycans in cells treated with the pharmacological sialyltransferase inhibitor Ac53FaxNeu5Ac and also 
in cells with complete SLC35A1 knockout (Büll, C., Heise, T., et al. 2015). Combination of the 
sialyltransferase inhibitor with the UDP-GlcNAc synthesis inhibitor 4-deoxy-GlcNAc abrogated 
labeling with Ac4ManNPoc indicating that this ManNAc analogue is converted into UDP-GlcNAc in 
case that the efflux of sialic acids is blocked. Next to the UDP-N-acetylglucosamine 2-epimerase 
domain of the bifunctional enzyme GNE, mammalian cells can express another GlcNAc 2-epimerase 
also known as renin-binding protein (RenBP). This GlcNAc 2-epimerase has been reported to catalyze 
ManNAc into GlcNAc, thereby deflecting the flux of ManNAc away from sialic acid synthesis 
(Figure 2) (Ghosh, S. and Roseman, S. 1965, Luchansky, S.J., Yarema, K.J., et al. 2003, Maru, I., 
Ohta, Y., et al. 1996, Takahashi, S., Takahashi, K., et al. 1999). Depending on the expression levels 
and activity of GlcNAc 2-epimerase, ManNAc analogues could enter the hexosamine biosynthesis 
pathway via this alternative metabolic route, resulting in the production of modified N-
Acetylgalactosamine (GalNAc), GlcNAc or other sugars.  
Next to the ManNAc analogues, recent studies indicate that sialic acid analogues can enter the 
hexosamine pathway under certain circumstance as well. Ahmed and co-workers reported that under 
starvation conditions, exogenous sialic acid is converted to UDP-GlcNAc to fuel the hexosamine 
biosynthesis pathway in cells. Presumably, sialic acid is degraded into ManNAc and pyruvate by N-
acetylneuraminate lyase and ManNAc is either recycled for sialic acid synthesis or can be converted 
into GlcNAc and other sugars derived from its metabolism (Badr, H.A., AlSadek, D.M.M., et al. 2017, 
Badr, H.A., AlSadek, D.M.M., et al. 2015, Varki, A., Schnaar, R.L., et al. 2015b). 
Altogether, these studies suggest that ManNAc and possibly sialic acid analogues can be 
interconverted and hence their modification could basically end up in all products of the hexosamine 
pathway. So far, it is largely unknown under which circumstances and to what extent ManNAc and 
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Effects on biological processes 
Natural ManNAc and sialic acid sugars are poorly taken up by cells, and as a consequence can be 
added to cell cultures at concentrations in the millimolar range without affecting cell proliferation or 
viability (Bardor, M., Nguyen, D.H., et al. 2005, Bork, K., Reutter, W., et al. 2005, Büll, C., Boltje, 
T.J., et al. 2013, Ghaderi, D., Taylor, R.E., et al. 2010, Han, S.S., Lee, D.E., et al. 2017, Keppler, O.T., 
Hinderlich, S., et al. 1999, Oetke, C., Brossmer, R., et al. 2002, Saxon, E., Luchansky, S.J., et al. 2002, 
Wang, J., Cheng, B., et al. 2015). Major differences exist between peracetylated ManNAc and sialic 
acid analogues with respect to their effects on biological functions. Generally, the acetyl groups that 
promote passive diffusion of ManNAc and sialic acid and are released by esterases were recently 
shown to induce non-enzymatic cysteine S-glycosylation at high sugar concentrations (2mM in cell 
lysate). The cellular effects of this reaction remain to be investigated, but this study indicates that care 
needs to be taken when using acetylated precursors at millimolar concentrations (Qin, W., Qin, K., et 
al. 2018). Furthermore, the toxicity profile of ManNAc and sialic acid analogues varies significantly 
depending on the type of modification (Almaraz, R.T., Mathew, M.P., et al. 2012). Therefore, we 
focus here only on the characteristics of peracetylated ManNAc (Ac4ManNAc) and sialic acid 
(Ac5Neu5Ac) and their commonly used azido variants Ac4ManNAz and Ac5SiaNAz.  
Peracetylated ManNAc and Ac4ManNAz affect proliferation and viability at concentrations above 100 
µM depending on the cell type (Aich, U., Campbell, C.T., et al. 2008, Almaraz, R.T., Aich, U., et al. 
2012, Charter, N.W., Mahal, L.K., et al. 2002, Han, S.S., Lee, D.E., et al. 2017, Hsu, T.L., Hanson, 
S.R., et al. 2007, Jones, M.B., Teng, H., et al. 2004, Kim, E.J., Jones, M.B., et al. 2004, Rochefort, 
M.M., Girgis, M.D., et al. 2014). At lower concentrations around 50 µM, Ac4ManNAz appears to be 
generally tolerated and allows sufficient incorporation into sialoglycans. Recent studies, however, 
report that peracetylated ManNAc analogues influence cellular function already at low micromolar 
concentrations. For instance, Ac4ManNAz as well as Ac4ManNAc reduced neurite outgrowth in 
primary mouse neuron cultures at 5 µM and showed cytotoxicity at 50 µM (Kang, K., Joo, S., et al. 
2015). In a sprouting assay using spheroids derived from human umbilical vein endothelial cells, 50 
µM ManNAc reduced the total capillary length by 75% compared to control (Bayer, N.B., Schubert, 
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Ac4ManNAz on human adenocarcinoma cells as well as umbilical cord blood-derived endothelial 
progenitor cells (Han, S.S., Lee, D.E., et al. 2017, Han, S.S., Shim, H.E., et al. 2018). They found that 
treatment with 10 µM Ac4ManNAz or higher resulted in the > 7 fold differential expression of more 
than 2000 genes compared to control cells affecting various cellular pathways. In particular treatment 
with 50 µM Ac4ManNAz induced strong changes in the expression of genes involved in the cell cycle, 
proliferation, adhesion and apoptosis. Accordingly, supplementation with 20 µM Ac4ManNAz or 
higher reduced cell growth, invasive properties and cellular respiration. Other tested parameters such 
as the tube-forming potential of the endothelial progenitor cells and LDL uptake were not significantly 
altered by Ac4ManNAz suggesting that this sugar does not generally influence all cellular functions.  
Altogether, these studies demonstrate that peracetylated ManNAc analogues, although useful for 
sialoglycan labeling, have a broad impact on the molecular and cellular level (Table II). Curiously, 
the mechanisms by which ManNAc and its analogues affect cellular processes are not known. The 
release of acetyl groups by esterases in the cytoplasm and the recently discovered non-enzymatic 
cysteine S-glycosylation could contribute to the described effects (Qin, W., Qin, K., et al. 2018). 
Another possibility is that ManNAc influences cellular processes by altering biochemical pathways or 
changing gene expression (Du, J., Meledeo, M.A., et al. 2009, Han, S.S., Lee, D.E., et al. 2017). 
Further studies are needed to unravel the effect of ManNAc and its analogues on these molecular 
processes. 
In comparison, peracetylated sialic acid analogues are less frequently used and only few studies have 
investigated their effects on biological processes. We have found that peracetylated sialic acid is well 
tolerated by cell lines even at concentrations above 2 mM without affecting proliferation or viability 
(van den Bijgaart, R.J.E., Kroesen, M., et al. 2019). Also, pretreatment of mouse melanoma cells with 
Ac5Neu5Ac for three days in vitro or intratumoral Ac5Neu5Ac injections for several weeks in vivo had 
no effect on melanoma growth in mice, indicating that peracetylated sialic acid does not alter overall 
cell behavior (Büll, C., Boltje, T.J., et al. 2018, Büll, C., Boltje, T.J., et al. 2013). In line with these 
findings, Ac4ManNAz affects cellular viability in vitro at concentrations above 100 µM whereas the 
corresponding sialic acid analogues Ac5SiaNAz showed no signs of cytotoxicity even at 
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peracetylated sialic acids are less cytotoxic than peracetylated ManNAc analogues and suggest that the 
effects detected with ManNAc are not solely caused by release of acetyl groups, but mediate by 
intracellular ManNAc. Clearly more detailed studies are required to assess the effects of both types of 
sugar analogues at the molecular level. 
Despite peracetylated ManNAc analogues affect cell proliferation and viability in vitro, no adverse 
effects have been reported so far for the in vivo use of ManNAc analogues. Bertozzi and colleagues 
have demonstrated the use of Ac4ManNAz for the labeling of sialoglycans in developing zebrafish 
embryos as well as in mice (Baskin, J.M., Dehnert, K.W., et al. 2010, Chang, P.V., Chen, X., et al. 
2009, Dehnert, K.W., Baskin, J.M., et al. 2012, Prescher, J.A., Dube, D.H., et al. 2004, Saxon, E. and 
Bertozzi, C.R. 2000). Malicdan and co-workers showed that continuous oral administration of 
Ac4ManNAc for more than 40 weeks was tolerated without affecting renal or liver function (Malicdan, 
M.C., Noguchi, S., et al. 2012). Accordingly, Reutter and co-workers found that injections with N-
Propanoylmannosamine (Ac4ManNProp) twice a day for up to 45 days were tolerated and allowed to 
replace about 60 % of the natural sialic acids in mice. Although no effects of the injections on the 
histological and physiological level were found, Ac4ManNProp injections strongly reduced the 
expression of polysialic acids (NCAM) in the brain without being incorporated (Gagiannis, D., 
Gossrau, R., et al. 2007). The consequences hereof for brain function were not assessed so far. We as 
well have not noticed adverse effects derived from repeated injections with alkyne-modified 
peracetylated ManNAc as well as sialic acid in mice (Büll, C., Heise, T., et al. 2015). Thus, 
peracetylated ManNAc and sialic acid analogues appear to be well tolerated in vivo, but more detailed 
studies are required to rule out possible effects on physiological processes. 
 
Applications of ManNAc and sialic acid analogues 
Both, ManNAc and sialic acid analogues are useful tools to introduce modified sialic acids into cell 
surface glycans, but their differences in chemical modification potential, incorporation efficiency, 
selectivity and effects on physiological processes should be taken into account when performing sialic 
acid glycoengineering experiments (Table I). Although, studies directly comparing ManNAc 
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allow for higher labeling efficiencies, have fewer effects on cell biology and are more specific for the 
sialic acid pathway. Furthermore, labeling of sialylated microorganisms e.g. Nontypeable 
Haemophilus influenzae that utilize ManNAc for energy production, but not for synthesizing sialic 
acids can only be achieved using sialic acid analogues (Apicella, M.A. 2012, Heise, T., Langereis, 
J.D., et al. 2018).  
However, depending on the application both ManNAc and sialic acid analogues are highly useful. For 
instance, both ManNAc and sialic acid analogues allow for the detection of and possibly rescue of 
genetic defects in the sialic acid biosynthesis pathway (Freeze, H.H. 2013). In a recent study, exome 
sequencing revealed mutations in NANS in a cohort of patients with infantile-onset severe 
developmental delay and skeletal dysplasia (van Karnebeek, C.D., Bonafe, L., et al. 2016). 
Accordingly, elevated levels of ManNAc were identified in serum and urine of the patients and 
fibroblasts cultured from these patients featured increased ManNAc-6-phosphate levels compared to 
control. Remarkably, no reduction in systemic sialic acid levels and sialylation was found, suggesting 
residual activity of the NANS mutants or efficient recycling of dietary sialic acids. However, in 
NANS-deficient zebrafish embryos, addition of sialic acid rescued abnormal skeletal development 
suggesting that the reduced sialic acid production from ManNAc is causative for the disease 
phenotype. ManNAl and SiaNAl were used to demonstrate the reduced NANS activity in patient 
fibroblasts. Whereas ManNAl was not incorporated into membrane sialoglycans, SiaNAl 
supplementation resulted in clear labeling. Similarly, ManNAl and SiaNAl were employed to 
demonstrate a genetic defect in the lysosomal sialic acid transporter sialin (SLC17A5) that leads to 
sialic acid storage disorder. In sialin-deficient patient fibroblasts, the addition of ManNAl, but not 
SiaNAl resulted in efficient labeling of surface sialoglycans (Gilormini, P.A., Lion, C., et al. 2016). 
Next to their potential diagnostic use, ManNAc and sialic acid analogues are also under investigation 
for the treatment of GNE myopathy, a rare disease resulting in muscular atrophy. GNE myopathy is 
caused by mutations either in the epimerase (GNE) or kinase (MNK) domain resulting in reduced 
sialic acid production (Carrillo, N., Malicdan, M.C., et al. 2018). The pathophysiology of GNE 
myopathy is not understood completely, but (pre-)clinical studies suggest that ManNAc analogues and 
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to reduce muscular atrophy (Carrillo, N., Malicdan, M.C., et al. 2018, Malicdan, M.C., Noguchi, S., et 
al. 2009, Malicdan, M.C., Noguchi, S., et al. 2012). 
Despite ManNAc and sialic acid analogs both are valuable probes to identify defects in GNE (MNK 
domain), NANS, NANP or sialin, defects downstream sialic acid synthesis might not be detected 
unequivocally. We have shown that defects inhibiting sialylation in the Golgi system that reduce sialic 
acid efflux can be detected with sialic acid analogues, but not with ManNAc analogues. Complete 
knockdown of the CMP-sialic acid transporter (SLC35A1) in haploid cells or pharmacological 
inhibition of sialyltransferases with fluorinated sialic acid reduced labeling of glycans with alkyne 
sialic acid about 90% of control, but only reduced labeling with alkyne ManNAc by about 50% (Büll, 
C., Heise, T., et al. 2015, Riemersma, M., Sandrock, J., et al. 2015). In line with the findings, Kohnz et 
al still observed labeling with ManNAz in CMAS knockdown cells (Kohnz, R.A., Roberts, L.S., et al. 
2016). Presumably, blocked sialylation results in the conversion of ManNAc in the hexosamine 
pathway into monosaccharides other than sialic acid. Overall, these studies are good examples for the 
effective use of ManNAc and sialic acid analogues to monitor the metabolic flux through the sialic 
acid pathway and to isolate defects in sialic acids biosynthesis on the biochemical level. ManNAc and 
sialic acid analogues can thus be applied to explore the interconnection of the sialic acid pathway with 
other glycosylation pathways. Furthermore, based on the analogues, assays can be developed to 
determine the severity of genetic effects for enzyme function and sialic acid production and to develop 
robust screening assays to select pharmaceuticals restoring the biochemical defects in the sialic acid 
biosynthesis pathway.  
 
Conclusion 
Sialic acids are at the center of numerous molecular interactions at the cells surface and associated 
with several pathologies including infection and cancer. Glycoengineering using ManNAc and sialic 
acid analogues has therefore a wide range of biological and therapeutic applications, but there are 
intrinsic differences between both sugars that should be taken into account. ManNAc and sialic acid 
analogues can show significant differences with respect to their incorporation efficiency into 
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lead to different results in glycoengineering experiments. ManNAc and sialic acid analogues should 
therefore be compared using parameters such as summarized in Table II to be able to select the best 
analogue depending on the type of application. Such comparative studies are especially needed, 
regarding the growing number of ManNAc and sialic acid analogues with one or more functionalities 
that is becoming available to probe and alter the biological functions of sialic acids in single cells and 
whole organisms. Comparative studies can be difficult to pursue for instance, because of limited 
availability of analogues or restricted access to technology to assess their metabolism and to quantify 
incorporation. These hurdles will be overcome with an increasing availability of ManNAc and sialic 
acid analogues, rapid progress in the development of robust readouts e.g. click chemistry, advances in 
the mass spectrometry of glycans and their metabolites and growing multidisciplinary research efforts. 
Eventually, these studies will enable researchers in the field of glycobiology and beyond to explore the 
numerous applications of sialic acid glycoengineering using ManNAc and sialic acid analogues. 
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Abbreviations 
ADP   Adenosine diphosphate 
ATP   Adenosine triphosphate 
CMAH   Cytidine-monophosphate-N-acetylneuraminic acid hydroxylase 
CMAS   CMP sialic acid synthase  
CMP   Cytidine monophosphate 
GalNAc  N-Acetylgalactosamine 
GlcNAc   N-acetylglucosamine 
GNE    UDP-GlcNAc 2-epimerase/ManNAc kinase 
KDN   2-keto-3-deoxy-D-glycero-D-galacto-nononic acid 
ManNAc  N-Acetylmannosamine  
MNK   ManNAc kinase 
NAL   N-acetylneuraminic acid lyase  
NANP    Neu5Ac-9-P-phosphatase 
NANS   N-acetylneuraminate synthase 
NCAM   Neural cell adhesion molecule 
Neu5Ac  N-Acetylneuraminic acid 
Neu5Gc   N-Glycolylneuraminic acid 
NPL   N-acetylneuraminate lyase 
Pep   Phosphoenolpyruvate 
PI   Inorganic phosphate 
RenBP   Renin-binding protein 
Siglec   Sialic acid-binding immunoglobulin-like lectin 
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Figure Legends 
Figure 1 Chemical structure of N-Acetylmannosamine (ManNAc) and N-Acetylneuraminic acid 
(Neu5Ac). 
 
Figure 2 Sialic acid biosynthesis pathway and entry points of ManNAc and sialic acid analogues. 
The de novo biosynthesis of sialic acid is derived from the metabolism of glucose. Three enzymatic 
steps convert glucose into uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the biochemical 
precursor for the biosynthesis of Neu5Ac as well as other carbohydrates. The bifunctional enzyme 
UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE) converts UDP-GlcNAc into N-
Acetylmannosamine (ManNAc) via its epimerase domain (GNE) and subsequently produces 
ManNAc-6-phosphate using its kinase activity (MNK). ManNAc-6-phosphate is converted into 
Neu5Ac-9-phosphate by the N-acetylneuraminate synthase (NANS) and dephosphorylated by 
Neu5Ac-9-P-phosphatase (NANP) to yield Neu5Ac. In the nucleus, Neu5Ac is conjugated with 
cytidine monophosphate (CMP) by the CMP sialic acid synthase (CMAS) and transported into the 
Golgi system via the CMP-sialic acid transporter SLC35A1.Cytosolic CMP-sialic acid levels regulate 
the de novo synthesis of sialic acids by feedback inhibition of GNE. In the Golgi, 20 sialyltransferase 
isoenzymes link sialic acid to glycans. Sialoglycans present at the cell surface or in intracellular 
compartments like lysosomes can be cleaved by sialidases to release free sialic acids. Free lysosomal 
sialic acids can be transported into the cytosol via the sialin (SLC17A5) transporter for recycling in the 
sialic acid biosynthesis pathway or degradation into ManNAc and pyruvate by N-acetylneuraminate 
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Figure 3 Reported ManNAc (blue) and sialic acid analogues (C-5 in red; C-9 in gray) developed for 
sialic acid glycoengineering. 1. (Collins, B.E., Fralich, T.J., et al. 2000); 2. (Chefalo, P., Pan, Y., et al. 
2006); 3. (Lieke, T., Gröbe, D., et al. 2011); 4. (Jacobs, C.L., Goon, S., et al. 2001, Kayser, H., Zeitler, 
R., et al. 1992, Keppler, O.T., Stehling, P., et al. 1995); 5, 26. (Dafik, L., d’Alarcao, M., et al. 2008, 
Hadfield, A.F., Mella, S.L., et al. 1983); 6, 10. (Stairs, S., Neves, A.A., et al. 2013); 7. (Cole, C.M., 
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29. (Büll, C., Heise, T., et al. 2017); 30. (Feng, L., Hong, S., et al. 2013); 31. (Homann, A., Qamar, R.-
u., et al. 2010); 32. (Dafik, L., d’Alarcao, M., et al. 2010); 37. (Xie, R., Hong, S., et al. 2012); 42. 
(Zeng, Y., Ramya, T., et al. 2009); 43. (Patterson, D.M., Nazarova, L.A., et al. 2012); 45. (Han, S., 
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Table I General considerations for ManNAc and sialic acid analogues. 




 Simple (1 step) modification 
 Only C-2 and C-4 modifications are 
tolerated by GNE, NANS and NANP  
 
 Size of modification is mainly limited 
by GNE  
 Does not allow conversion into 
corresponding sialic acid analogues 
with C-3 or C-4 modifications 
 Suitable for peracetylation or other 
prodrug modifications  
 Modification more challenging  
 Small modifications from C-3 to C-9 
are generally tolerated by enzymes 
involved in sialylation  
 Chemo-enzymatic synthesis from 
ManNAc possible 
 C-3 to C-9 modification feasible (C-
3, C-5, C-7, C-9 achieved; C-4 and C-
8 possible) 
 Suitable for peracetylation or other 
prodrug modifications 
Metabolism 
 Uptake of unprotected ManNAc 
analogues is poor (1-10 mM) and 
potentially mediated via a so far 
unknown transporter 
 
 Peracetylation improves membrane 
permeability (100-1000 times higher 
uptake) 
 Conversion into sialic acids via three 
rate-limiting enzymes 
 Utilization in hexosamine pathway 
possible through conversion into 
GlcNAc by GlcNAc 2-epimerase 
 Uptake of unprotected sialic acid is 
poor (1-10 mM) and potentially 
mediated by pinocytosis into 
lysosomes and export into cytosol via 
SLC17A5 
 Peracetylation improves membrane 
permeability (100-1000 times higher 
uptake) 
 Directly available for CMP activation 
by CMAS after deacetylation 
 Utilization in hexosamine pathway 
possible through degradation into 
ManNAc by NPL  
Applications 
 Restricted to cells/species expressing 
GNE, NANS and NANP 
 Sialic acid glycoengineering  
 Metabolic flux analysis  
 Detection of genetic effects upstream 
of GNE (MNK domain), NANS or 
NANP 
 Incorporation independent from 
GNE, NANS and NANP  
 Sialic acid glycoengineering 
 Metabolic flux analysis 
 Detection of genetic effects 
downstream of NANP and in the 
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Table II Criteria for the evaluation of ManNAc and sialic acid analogues using the example of 
peracetylated ManNAc and sialic acid and their frequently used C-5 alkyne and azido variants. 
 
 Ac4ManNAc/Az/Al Ac5SiaNAc/Az/Al References 
Synthesis 
 2 steps  8 steps (Saxon, E., 
Luchansky, S.J., et al. 
2002) 
Uptake 
 Passive diffusion and 
deacetylation by esterases 
 Passive diffusion and 
deacetylation by esterases 
(Wang, Z., Du, J., et 
al. 2009) 
Effects on sialic 
acid biosynthesis 
enyzmes  
 Not reported  Not reported  
Incorporation 
efficiency in vitro 
 2-4 times lower compared 
to sialic acid analogues in 
THP-1, Jurkat, HEK293 and 
HL-60 cells at 100 µM 
 Low/no incorporation into 
secreted transferrin 
 2-4 times higher compared 
to ManNAc analogues in 
THP-1, Jurkat, HEK293 and 
HL-60 cells at 100 µM 
 Incorporation into secreted 
transferrin 
(Büll, C., Heise, T., 




 Incorporation detectable in 
SLC35A1 knockout cells 
 Sialyltransferase inhibitor 
reduces labeling by 50%  
 Incorporation into sialidase-
resistant cell surface 
glycans 
 Indications for metabolism 
in hexosamine pathway 
 No incorporation into 
SLC35A1 knockout cells  
 Sialyltransferase inhibitor 
reduces labeling by 80% 
 Selective utilization in the 
sialic acid biosynthesis 
pathway 
(Büll, C., Heise, T., 
et al. 2015, Dube, 
D.H., Prescher, J.A., 
et al. 2006, 
Luchansky, S.J., 
Yarema, K.J., et al. 
2003, Neves, A.A., 
Stockmann, H., et al. 
2011) 
Off-target effects 
 Acetyl groups can induce 
cysteine S-glycosylation (2 
mM) 
 Inhibition of proliferation 
and cytotoxicity >50 µM 
 Induction of differential 
gene expression  
 Reduction of cellular 
respiration rate and 
enhanced ROS production 
>20 µM  
 Inhibition of neurite 
outgrowth and capillary 
sprouting >50 µM 
 Acetyl groups can induce 
cysteine S-glycosylation (2 
mM) 
 No cytotoxic effects found 
at concentration up to 2 mM 
 No effects on cellular 
function reported 
(Bayer, N.B., 
Schubert, U., et al. 
2013, Han, S.S., Lee, 
D.E., et al. 2017, 
Han, S.S., Shim, 
H.E., et al. 2018, 
Jones, M.B., Teng, 
H., et al. 2004, Kang, 
K., Joo, S., et al. 
2015, Qin, W., Qin, 
K., et al. 2018, van 
den Bijgaart, R.J.E., 






 2 times lower systemic 
incorporation compared to 
sialic acid analogue  
 No labeling of brain 
sialoglycans (liposome 
formulation) 
 No toxicity reported 
 2 times higher systemic 
incorporation compared to 
ManNAc analogue 
 Effective labeling of brain 
sialoglycans (liposome 
formulation)  
 No toxicity reported 
(Büll, C., Heise, T., 
et al. 2015, Xie, R., 
Dong, L., et al. 2016) 
Diagnostic Use 
 Detection of genetic defects 
in NANS in patient-derived 
fibroblasts 
 Detection of genetic defects 
in NANS in patient-derived 
fibroblasts 
(van Karnebeek, 
C.D., Bonafe, L., et 
al. 2016) 
Therapeutic Use 
 Oral administration 
improves muscle phenotype 
in GNE myopathy mouse 
model 
 Not evaluated (Malicdan, M.C., 
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